Loading...
Docoh

Allogene Therapeutics (ALLO)

News

From Benzinga Pro
What 5 Analyst Ratings Have To Say About Allogene Therapeutics
10 Aug 22
Analyst Ratings
Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
10 Aug 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Oppenheimer Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $35
10 Aug 22
News, Price Target, Analyst Ratings
Oppenheimer analyst Mark Breidenbach maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $40 to $35.
RBC Capital Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $32
10 Aug 22
News, Price Target, Analyst Ratings
RBC Capital analyst Luca Issi maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $35 to $32.
Raymond James Downgrades Allogene Therapeutics to Market Perform
10 Aug 22
News, Downgrades, Analyst Ratings
Raymond James analyst Dane Leone downgrades Allogene Therapeutics (NASDAQ:ALLO) from Outperform to Market Perform.
Allogene Therapeutics: Q2 Earnings Insights
9 Aug 22
Earnings
Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Allogene Therapeutics Q2 EPS $(0.52) Beats $(0.61) Estimate
9 Aug 22
Earnings, News
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.61) by 14.75 percent. This is a 1.89 percent increase over losses of $(0.53) per share
Earnings Scheduled For August 9, 2022
9 Aug 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
20 Jul 22
Analyst Color, Penny Stocks, Small Cap, Top Stories, Analyst Ratings, Trading Ideas
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a list of potential short squeeze stocks based on S3's proprietary Squeeze Score rating
Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022
15 Jul 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
12 Health Care Stocks Moving In Friday's Pre-Market Session
15 Jul 22
Pre-Market Outlook, Markets, Movers
Goldman Sachs Upgrades Allogene Therapeutics to Buy, Raises Price Target to $32
15 Jul 22
News, Upgrades, Price Target, Analyst Ratings
Goldman Sachs analyst Salveen Richter upgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Buy and raises the price target from $9 to $32.
89 Biggest Movers From Friday
21 Jun 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
3 Jun 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
What 4 Analyst Ratings Have To Say About Allogene Therapeutics
3 Jun 22
Analyst Ratings
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:
Baird Initiates Coverage On Allogene Therapeutics with Neutral Rating, Announces Price Target of $11
3 Jun 22
News, Price Target, Initiation, Analyst Ratings
Baird analyst Jack Allen initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Neutral rating and announces Price Target of $11.
Goldman Sachs Maintains Neutral on Allogene Therapeutics, Lowers Price Target to $9
24 May 22
News, Price Target, Analyst Ratings
Goldman Sachs maintains Allogene Therapeutics (NASDAQ:ALLO) with a Neutral and lowers the price target from $12 to $9.

Press releases

From Benzinga Pro
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
9 Aug 22
Earnings, News, Health Care, Press Releases
U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry's First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2 Protocol and Chemistry
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
3 Aug 22
News, Press Releases
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
27 Jul 22
News, Press Releases
SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)
Thinking about buying stock in Allogene Therapeutics, Neximmune, Vertical Aerospace, Sonim Technologies, or DigitalBridge?
15 Jul 22
Opinion, Press Releases
NEW YORK, July 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALLO, NEXI, EVTL, SONM, and DBRG.
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
8 Jun 22
Health Care, Press Releases
RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American Society of Hematology (ASH) 2021